Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zoldonrasib + cetuximab + leucovorin + fluorouracil + oxaliplatin
- Development stage
- Unknown
- Lead developer
- REVOLUTION Medicines
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
zoldonrasib + cetuximab + leucovorin + fluorouracil + oxaliplatin is an investigational combination regimen being evaluated for the treatment of gastrointestinal solid tumors, specifically KRAS G12D-mutant colorectal cancer. The regimen combines zoldonrasib (RMC-9805), an oral, mutant-selective covalent tri-complex inhibitor of the active GTP-bound state of KRAS G12D, with cetuximab, an anti-EGFR monoclonal antibody, and the mFOLFOX6 chemotherapy backbone (leucovorin, fluorouracil, and oxaliplatin). This combination is designed to achieve deeper and more durable inhibition of the RAS/MAPK pathway by simultaneously targeting mutant KRAS G12D and blocking EGFR-mediated feedback reactivation, while utilizing standard-of-care chemotherapy to enhance cytotoxic tumor cell death. The regimen is being investigated by Revolution Medicines in the Phase 1/2 RMC-GI-102 platform study (NCT06445062).
- Other names
- RMC-9805 + cetuximab + leucovorin + fluorouracil + oxaliplatinRMC-9805 + cetuximab + mFOLFOX6zoldonrasib + cetuximab + mFOLFOX6
02
Targets
DNAEGFR (Epidermal growth factor receptor)KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)PPIA (Peptidyl-prolyl cis-trans isomerase A)TS (Thymidylate synthase)
Beyond the preview
Go deeper on zoldonrasib + cetuximab + leucovorin + fluorouracil + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zoldonrasib + cetuximab + leucovorin + fluorouracil + oxaliplatin.